Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Vila Nova de Gaia
Clinical trial register · Portugal

Clinical Trials in Vila Nova de Gaia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Portugal and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1100 matching records held by the registry are in this view. Synced 03 Oct 2026, 03:16 UTC
1100
Studies in scope
all four open statuses
535
Recruiting now
open to new participants
284
Lead sponsors
across recruiting studies
Top sites
Lisbon 683 Porto 541 Coimbra 258 Braga 180 Vila Nova de Gaia 108
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC10 Novartis Pharmaceuticals7 AstraZeneca7 Novo Nordisk A/S7 Amgen6
Site location
Lisbon683 Porto541 Coimbra258 Braga180 Vila Nova de Gaia108
All 96 locations
Target enrolment
to

Trials with a site in Vila Nova de Gaia

108 of 1100 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Portugal
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Vila Nova de Gaia, Lisbon, Loures, Porto
2026-12-16
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Lisbon, Vila Nova de Gaia, Braga, Porto
2026-11-30
Not yet open
Family-centred Pulmonary Rehabilitation to Empower Carers
NCT07791147Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial, Asthma, Lung Neoplasms
Aveiro University
Not applicable
120
Aveiro, Santa Maria da Feira, Figueira da Foz Municipality, Lisbon, Matosinhos Municipality, Vila Nova de Gaia
2026-09
Recruiting
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504Overweight, Obesity
DrugCagrilintide
Novo Nordisk A/S
Phase 3
285
Caldas da Rainha, Figueira da Foz Municipality, Leiria, Lisbon, Vila Nova de Gaia
2026-08-04
Not yet open
Evaluation of Calcified Coronary Lesion Preparation With the Naviscore Scoring Balloon
NCT07650578Coronary Arterial Disease (CAD), Calcific Coronary Arteriosclerosis
University of Mons
Not applicable
200
Vila Nova de Gaia
2026-07
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
DrugsCagriSema·Semaglutide
Novo Nordisk A/S
Phase 3
2,500
Riachos, Torres Novas, Almada, Caldas da Rainha, Figueira da Foz Municipality, Lisbon, Senhora Da Hora, Matosinhos, Vila do Conde, Vila Nova de Gaia
2026-05-21
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939HER2-positive Breast Cancer
DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine
Hoffmann-La Roche
Phase 2/3
650
Amadora-Lisbon, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
2026-05-21
Not yet open
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107Obesity, Overweight, Diabetes Mellitus, Type 2
DrugsNNC0487-0111·Semaglutide
Novo Nordisk A/S
Phase 3
1,000
Alcabideche, Almada, Braga, Lisbon, Porto, Senhora Da Hora, Matosinhos, Vila Nova de Gaia
2026-05-20
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954Diabetes Mellitus, Type 2
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
270
Coimbra, Ponte de Lima, Vila do Conde, Vila Nova de Gaia
2026-04-17
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Almada, Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2026-03-05
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Porto, Vila Nova de Gaia
2026-02-11
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Braga, Porto, Viana do Castelo, Vila Nova de Gaia
2026-02-05
Recruiting
PERFECT - Portuguese Evolut Registry Studying the Outcomes of Medtronic Evolut™ FX+ TAVI System by Evaluating an Optimal Care Pathway for TAVI
NCT07343674Severe Symptomatic Aortic Stenosis (Defined as New York Heart Association (NYHA) Class ≥ II)
Portuguese Association of Interventional Cardiology
Observational
500
Coimbra, Lisbon, Funchal, Porto, Vila Nova de Gaia, Evora
2026-01-14
Recruiting
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
NCT07222137Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
150
Braga, Matosinhos Municipality, Porto, Viana do Castelo, Vila Nova de Gaia
2026-01-12
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
460
Porto, Vila Nova de Gaia
2026-01-08
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399Squamous Cell Carcinoma of Head and Neck
DrugsAmivantamab·Cisplatin·Carboplatin·Pembrolizumab
Janssen Research & Development, LLC
Phase 3
500
Lisbon, Portimão, Porto, Vila Nova de Gaia
2025-12-03
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Lisbon, Porto, Vila Nova de Gaia
2025-11-28
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Torres Novas, Lisbon, Porto, Vila Nova de Gaia
2025-11-19
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Braga, Loures, Porto, Vila Nova de Gaia
2025-10-24
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
100
Lisbon, Vila Nova de Gaia
2025-10-21
By invitation
Effects of a Virtual Reality-based Brain-Machine Interface Protocol in Spinal Cord Injury
NCT07732868Spinal Cord Injury, Able Bodied, Traumatic Spinal Cord Injuries, Paraplegia, Spinal
José Gabriel da Silva Figueiredo
Not applicable
20
Aveiro, Vila Nova de Gaia
2025-07-22
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Carnaxide, Vila Franca de Xira, Vila Nova de Gaia
2025-07-16
Recruiting
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
NCT06991114Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA
Artiva Biotherapeutics, Inc.
Phase 2
90
Vila Nova de Gaia
2025-07-09
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Almada, Coimbra, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2025-06-25
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Carnaxide, Vila Nova de Gaia, Aveiro, Braga, Coimbra, Leiria, Setúbal
2025-05-08
By invitation
Reengineering Cervical Cancer Screening for the 21st Century: Joint Action for a Novel Up-to-date and Sustainable Screening Program
NCT06915610Cervical Cancer Screening
Instituto de Saude Publica da Universidade do Porto
Not applicable
5,700
Vila Nova de Gaia
2025-04-10
Recruiting
A Modified Baveno Classification of Obstructive Sleep Apnoea Based on Sleepiness and Cardiovascular Scores
NCT06861686Obstructive Sleep Apnea (OSA)
Wissenschaftliches Institut Bethanien e.V
Observational
1,800
Vila Nova de Gaia, Loures
2025-03-24
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Almada, Matosinhos Municipality, Vila Nova de Gaia
2025-03-18
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,088
Coimbra, Ponte de Lima, Vila Nova de Gaia, Almada, Lisbon
2025-03-03
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Lisbon, Ponte de Lima, Vila Nova de Gaia
2025-02-25
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
Senhora Da Hora, Matosinhos, Lisbon, Porto, Vila Nova de Gaia
2025-02-10
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Braga, Coimbra, Lisbon, Portimão, Porto, Senhora da Hora, Vila Nova de Gaia
2025-01-28
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Coimbra, Lisbon, Ponte de Lima, Vila Nova de Gaia
2025-01-15
Recruiting
UP STUDY - Decipher Persistent Critical Illness Through in Deep Clinical Phenotyping.
NCT07510776Critical Illness, Recovery Outcomes, Critical Care, Intensive Care, Critical Care
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Observational
7,000
Lisbon, Vila Nova de Gaia
2025-01-13
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
DrugsLazertinib·Amivantamab
Janssen Research & Development, LLC
Phase 2
480
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2024-12-16
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Braga, Vila Nova de Gaia
2024-12-09
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Lisbon, Vila Nova de Gaia
2024-12-04
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245Patients With Non-Small Cell Lung Cancer
DrugsTedopi·Docetaxel
OSE Immunotherapeutics
Phase 3
363
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2024-12-03
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Lisbon, Vila Nova de Gaia
2024-11-11
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Braga, Vila Nova de Gaia
2024-10-18
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
DrugIanalumab
Novartis Pharmaceuticals
Phase 2
200
Coimbra, Lisbon, Vila Nova de Gaia
2024-10-09
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Loures, Vila Franca de Xira, Porto, Vila Nova de Gaia, Coimbra, Faro, Lisbon, Setúbal
2024-09-27
Recruiting
Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy
NCT06880029Triple Negative Breast Cancer (TNBC)
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Phase 1/2
20
Vila Nova de Gaia
2024-09-01
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Braga, Vila Nova de Gaia
2024-08-19
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Lisbon, Porto, Vila Nova de Gaia
2024-07-31
By invitation
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
680
Amadora, Faro, Guarda, Guimarães, Vila Nova de Gaia
2024-07-30
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
NCT06445023Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
963
Aveiro, Braga, Coimbra, Lisbon, Matosinhos Municipality, Porto, Setúbal, Vila Nova de Gaia
2024-07-11
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
DrugsNavtemadlin·Jakavi·Ruxolitinib
Kartos Therapeutics, Inc.
Phase 3
600
Aveiro, Braga, Lisbon, Vila Nova de Gaia
2024-06-03
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Guimarães, Coimbra, Almada, Braga, Guarda, Porto, Vila Nova de Gaia
2024-05-20
Active, closed
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
DrugNerandomilast
Boehringer Ingelheim
Phase 3
1,666
Braga, Coimbra, Lisbon, Matosinhos Municipality, Vila Nova de Gaia
2024-05-06
Active, closed
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408Sjögren's Syndrome (SS)
DrugDazodalibep
Amgen
Phase 3
434
Lisbon, Ponte de Lima, Vila Nova de Gaia
2024-04-08
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588Neoplasms, Head and Neck
DrugDostarlimab
GlaxoSmithKline
Phase 3
864
Coimbra, Faro, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2024-03-21
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Alcabideche, Braga, Coimbra, Vila Nova de Gaia
2024-03-07
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744Follicular Lymphoma (FL)
DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine
Genmab
Phase 3
1,095
Lisbon, Vila Nova de Gaia, Porto
2024-02-05
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga
Merck Sharp & Dohme LLC
Phase 3
1,314
Alcabideche, Vila Nova de Gaia, Braga, Lisbon, Porto
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Lisbon, Funchal, Vila Nova de Gaia
2023-12-15
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Lisbon, Vila Nova de Gaia
2023-12-15
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Lisbon, Vila Nova de Gaia, Porto
2023-12-13
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2023-12-11
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Coimbra, Lisbon, Vila Nova de Gaia
2023-12-07
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Braga, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-10-25
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Amadora, Braga, Lisbon, Porto, Vila Nova de Gaia, Vila Real
2023-10-05
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Faro, Lisbon, Loures, Porto, Vila Nova de Gaia
2023-09-14
Recruiting
The ReTAVI Prospective Observational Registry
NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction
Institut für Pharmakologie und Präventive Medizin
Observational
250
Carnaxide, Vila Nova de Gaia
2023-09-05
Recruiting
Improving Response to Chemotherapy by Adding Physical Exercise in the Neoadjuvant Setting of Breast Cancer Patients
NCT05976815Breast Cancer
University Institute of Maia
Not applicable
86
Vila Nova de Gaia
2023-07-31
Recruiting
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
NCT04861805Symptomatic Aortic Stenosis
P+F Products + Features GmbH
Not applicable
267
Lisbon, Carnaxide, Vila Nova de Gaia, Evora
2023-07-03
Active, closed
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576Lupus Erythematosus, Systemic
DrugCenerimod
Viatris Innovation GmbH
Phase 3
451
Amadora, Faro, Guarda, Guimarães, Lisbon, Vila Nova de Gaia
2023-06-26
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
DrugsMilvexian·Apixaban
Janssen Research & Development, LLC
Phase 3
20,284
Coimbra, Covilha, Figueira da Foz Municipality, Lisbon, Santa Maria da Feira, Torres Novas, Vila Nova de Gaia, Vila Real
2023-04-11
Active, closed
The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)
NCT06416644Lower Limb Ischemia, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, Chronic Limb Ischemia
Hospital do Divino Espírito Santo de Ponta Delgada
Not applicable
100
Faro, Ponta Delgada, Almada, Penafiel, Vila Nova de Gaia, Angra do Heroísmo, Coimbra, Guimarães
2023-04-01
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Amadora, Braga, Guimarães, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2023-03-31
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Almada, Braga, Lisbon, Porto, Vila Nova de Gaia
2023-03-29
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Coimbra, Lisbon, Vila Nova de Gaia
2023-03-23
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Braga, Lisbon, Vila Nova de Gaia
2023-03-02
Active, closed
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
NCT05620407Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
513
Lisbon, Vila Nova de Gaia
2023-01-12
Recruiting
RehabGBs: Rehabilitation in People With Guillain-Barré Syndrome
NCT05461898Guillain-Barré Syndrome
Centro de Reabilitacao do Norte
Not applicable
74
Vila Nova de Gaia
2023-01-01
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole
Eli Lilly and Company
Phase 3
8,000
Almada, Lisbon, Vila Nova de Gaia
2022-10-04
Active, closed
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484Colitis, Ulcerative
DrugsJNJ-78934804·Golimumab·Guselkumab
Janssen Research & Development, LLC
Phase 2
577
Lisbon, Loures, Portimão, Santa Maria da Feira, Vila Nova de Gaia
2022-09-19
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 2
240
Carnaxide, Coimbra, Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Active, closed
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 3
412
Lisbon, Porto, Vila Nova de Gaia
2022-08-10
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Braga, Carnaxide, Lisbon, Loures, Porto, Setúbal, Vila Franca de Xira, Vila Nova de Gaia
2022-05-30
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
DrugApremilast
Amgen
Phase 3
60
Lisbon, Ponte de Lima, Porto, Vila Nova de Gaia
2022-03-17
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Erbitux·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-12-10
Active, closed
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
NCT04812925Primary Immune Thrombocytopenia
DrugEfgartigimod PH20
argenx
Phase 3
173
Lisbon, Porto, Vila Nova de Gaia
2021-11-17
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Porto, Vila Nova de Gaia
2021-10-06
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Lisbon, Guimarães, Loures, Porto, Vila Nova de Gaia, Vila Real
2021-08-27
Active, closed
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT04964934ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Ribociclib·Abemaciclib
AstraZeneca
Phase 3
315
Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-06-30
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Porto, Vila Nova de Gaia
2021-05-10
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Braga, Lisbon, Porto, Vila Nova de Gaia
2021-02-23
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
DrugsCamizestrant·Anastrozole·Palbociclib
AstraZeneca
Phase 3
1,371
Braga, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia
2021-01-28
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 2
220
Almada, Aveiro, Guimarães, Lisbon, Loures, Porto, Vila Nova de Gaia, Vila Real
2020-12-18
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
1,600
Guimarães, Lisbon, Loures, Matosinhos Municipality, Porto, Vila Nova de Gaia
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
DrugsAdagrasib·Pembrolizumab
Mirati Therapeutics Inc.
Phase 2/3
626
Coimbra, Guimarães, Lisbon, Porto, Vila Nova de Gaia
2020-12-02
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
DrugsAmivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 3
308
Lisbon, Porto, Vila Nova de Gaia
2020-10-13
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone
Acerta Pharma BV
Phase 3
611
Braga, Lisbon, Matosinhos Municipality, Porto, Vila Nova de Gaia
2020-10-08
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Erbitux·Cetuximab
AstraZeneca
Phase 3
370
Coimbra, Porto, Vila Nova de Gaia
2020-10-02
Recruiting
International CIPN Assessment and Validation Study
NCT04633655Chemotherapy-induced Peripheral Neuropathy, Quality of Life
University of Milano Bicocca
Observational
1,000
Vila Nova de Gaia
2020-06-08
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin
Takeda
Phase 3
354
Santa Maria da Feira, Vila Nova de Gaia, Lisbon, Porto
2020-01-10
Active, closed
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 3
896
Vila Nova de Gaia, Coimbra, Guimarães, Porto
2019-09-05
Active, closed
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
NCT03992417Dermatitis Atopic
DrugDupilumab
Sanofi
Observational
955
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2019-06-11
Active, closed
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308Psoriatic Arthritis
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
964
Vila Nova de Gaia, Ponte de Lima, Aveiro, Braga, Lisbon
2019-03-25
Active, closed
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850Immunoglobulin A Nephropathy
DrugsSparsentan·Irbesartan·Dapagliflozin
Travere Therapeutics, Inc.
Phase 3
406
Coimbra, Lisbon, Loures, Setúbal, Vila Nova de Gaia
2018-12-11
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
DrugCeralasertib
AstraZeneca
Phase 2
273
Lisbon, Loures, Porto, Vila Nova de Gaia
2018-03-07
Recruiting
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
NCT02834884All Tumor Types
European Organisation for Research and Treatment of Cancer - EORTC
Observational
4,975
Coimbra, Lisbon, Porto, Vila Nova de Gaia
2017-05-03
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Vila Nova de Gaia
2016-12
Active, closed
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159Rheumatoid Arthritis
DrugsHumira·Adalimumab·Upadacitinib
AbbVie
Phase 3
1,629
Lisbon, Vila Nova de Gaia, Braga, Porto, Viana do Castelo
2015-12-01
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
Amadora, Coimbra, Lisbon, Porto, Vila Nova de Gaia
2013-09-25
Active, closed
Psoriasis Longitudinal Assessment and Registry
NCT00508547Psoriasis
Janssen Scientific Affairs, LLC
Observational
20,167
Braga, Lisbon, Porto, Vila Nova de Gaia
2007-06-21
Recruiting
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
NCT02832245Venous Thromboembolism
Manuel Monreal
Observational
120,000
Vila Nova de Famalicão, Senhora da Hora, Porto, Santa Maria da Feira, Almada, Vila Nova de Gaia
2001-03
Rows per page Showing 1–108 of 108
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Portuguese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 3 October 2026. https://priyalifescience.com/clinical-trials-portugal/city/vila-nova-de-gaia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Portugal and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,100 studies in total at the last sync on 03 Oct 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 108 of those studies with a site in Vila Nova de Gaia.

How many clinical trials are recruiting in Vila Nova de Gaia?

55 of the 108 studies on this page are recruiting new participants as of the 03 Oct 2026, 03:16 UTC sync. A further 5 have not yet opened recruitment, 44 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Vila Nova de Gaia), 108 studies
PhaseStudiesRecruitingShare
Phase 3672762%
Phase 2141013%
Observational11810.2%
Not applicable837.4%
Phase 1322.8%
Phase 2/3332.8%
Phase 1/2221.9%

Most active sponsors

Lead sponsors with the most studies (Vila Nova de Gaia)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC103
AstraZeneca71
Novartis Pharmaceuticals73
Novo Nordisk A/S74
Amgen65
Hoffmann-La Roche52
argenx42
Bristol-Myers Squibb40
AbbVie30
Eli Lilly and Company32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.